A primary goal of the clinical trials efforts of UPCI is to design, implement and analyze innovative, investigator-initiated pilot and phase 1 clinical trials. The development, initiation, implementation and completion of UPCI investigational studies receive substantial and essential support from UPCI Clinical Research Services (CRS). In 2008, 349 of the 1158 total UPCI patients (30%) participating in interventional clinical trials were entered onto institutional studies initiated by UPCI investigators. These investigatorinitiated trials focus on translational research and involve investigators from all of the translational and disease-specific programs of UPCI. Protocol-Specific Research Support has been instrumental in enabling several of these trials. Review of trials supported in the last grant cycle shows that the many PSRS supported trials advanced to the point of support by other mechanisms and/or publication of results. Requests for PSRS support of novel pilot or innovative phase I clinical trials are made by the PI at the time of submission of the trial to the Protocol Review Committee (PRC). Trials are evaluated for innovation and novelty, as well as availability of other sources of support, at the time of PRC submission. Trials with potential to be supported by PSRS funds are forwarded to the Associate Director of Clinical Investigation who makes recommendations to the Director of UPCI for final approval. Funds are used to support the effort of expert research nurses, termed Clinical Research coordinators, who can assist investigators with all aspects of trial implementation and execution.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-26
Application #
8705428
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$95,595
Indirect Cost
$32,356
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Zahorchak, Alan F; Macedo, Camila; Hamm, David E et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol 323:9-18
Rogers, Meredith C; Lamens, Kristina D; Shafagati, Nazly et al. (2018) CD4+ Regulatory T Cells Exert Differential Functions during Early and Late Stages of the Immune Response to Respiratory Viruses. J Immunol 201:1253-1266
Jing, Y; Nguyen, M M; Wang, D et al. (2018) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene 37:638-650
Singh, Krishna B; Ji, Xinhua; Singh, Shivendra V (2018) Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Mol Cancer Ther 17:2079-2090
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15
Gao, Ying; Tan, Jun; Jin, Jingyi et al. (2018) SIRT6 facilitates directional telomere movement upon oxidative damage. Sci Rep 8:5407
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Santos, Patricia M; Butterfield, Lisa H (2018) Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology 155:1684-1686
Liu, Zuqiang; Ge, Yan; Wang, Haiyan et al. (2018) Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nat Commun 9:4682

Showing the most recent 10 out of 1187 publications